A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Exclusion Criteria

• •1. Patients who have had other cancer(s) within 5 years prior to the first dose, except for locally curable cancers that have been apparently cured;
• •2. Patients with unstable primary central nervous system (CNS) tumors or CNS metastases;
• •3. Patients who have an active autoimmune disease or have had an autoimmune disease with risk of recurrence;
• •4. Patients who have active or history of interstitial lung disease or non-infectious pneumonia;
• •5. Patients who have a history of severe allergic reaction to any component of ICP-189 tablets or anti-PD-1 antibody (\> grade 3 assessed by CTCAE 5.0).